

SELL BHEL

193


Tripped by approval delays

Company Update

Target Price (INR)

| Last Price (INR) | 266.2 |
|----------------------|----------------|
| Bloomberg code | BHEL IN |
| Reuters code | BHEL.BO |
| Avg. Vol. (3m)(mn) | 3.59 |
| Avg. Val.(3m)(INRmn) | 914 |
| 52-wk H/L (INR) | 300 / 194 |
| Sensex | 28,236 |
| MCAP (INRbn/USDbn) | 651.43 / 10.20 |

| Shareholding (%) | 03/15 | 06/15 |
|------------------|-------|-------|
| Promoters | 63.1 | 63.1 |
| MFs, FIs, Banks | 17.3 | 17.3 |
| FIIs | 16.1 | 16.1 |
| Public | 2.3 | 2.2 |
| Others | 1.3 | 1.3 |



| 2.8 16 | 6.4 15 | .3 |
|--------|--------|----|
| 2.5 10 | 0.2 4 | .9 |
| Ī | - | |

| Financials (INRmn) | 03/15 | 03/16f | 03/17f |
|--------------------|---------|---------|---------|
| Sales | 301,830 | 295,385 | 363,645 |
| YoY (%) | -23 | -2 | 23 |
| EBITDA (%) | 8.2 | 9.0 | 12.3 |
| A.PAT | 14,852 | 17,640 | 31,132 |
| Sh o/s (diluted) | 2,448 | 2,448 | 2,448 |
| A.EPS (INR) | 6.1 | 7.2 | 12.7 |
| YoY (%) | -57 | 19 | 76 |
| D/E (x) | -0.4 | -0.4 | -0.4 |
| P/E (x) | 43.9 | 36.9 | 20.9 |
| EV/E (x) | 21.4 | 19.0 | 11.1 |
| RoCE (%) | 5 | 5 | 9 |
| RoE (%) | 4 | 5 | 8 |

| Quarterly Trends | 09/14 | 12/14 | 03/15 | 06/15 |
|------------------|--------|--------|---------|--------|
| Sales (INRmn) | 61,440 | 61,980 | 126,860 | 43,617 |
| PAT (INRmn) | 1,248 | 2,126 | 9,512 | 339 |

New orders bagged recently have taken more time to start execution, which explains the continuing revenue deceleration and profit dip in Q1. Excluding forex income of INR1.7bn, the PAT is also in the red. Revenue contribution from new orders is likely to start from Q3. Apart from 4GW order booked in Q1, it is L1 in another 5GW worth of orders. Our forecasts are unchanged and assume 18GW of orders over FY16f-17f. Delays in redressal of the distribution side problems threatens to spill over at some point and impact the continuity of order flows. Stranded project status is unchanged and likely to remain so in the foreseeable future. Maintain Sell with TP of INR193/share at 15x P/E.

Lower revenue and operating de-leverage lead to EBITDA level loss

The 15% y-o-y revenue deceleration in Q1 was similar to the Mar15 level. Execution has not improved in-line with the improved order backlog in the past one-year. This was on account of lack of traction in execution of new orders due to delays in clearances for the projects. Accordingly, there was delay in delivery of materials despite them being ready at the company's factories. The lower revenue was primarily responsible for the -4.8% EBITDA margin during the quarter. Gross margins at 45.5% were better than the 43.9% reported in FY15. Management expects execution to pick up from Q3. Forex gains of INR1.7bn boosted the other income and PAT in Q1.

Order prospects secure with L1 of 5GW worth of projects

Q1 order inflow was strong on booking of 4GW of project order from the Telangana SEB (as already announced). Further, the company is L1 in another 5GW worth of projects from NTPC and other SEBs. There is a 2x660MW tender coming up in Bangladesh. The management expects 15-20 GW worth of orders to be finalised during FY16 and FY17 each. Further, tenders for guns for navy, 15 high speed trains and diesel/electric locomotives are also expected to be finalised in the current fiscal.

We maintain forecasts, wage impact to constrain FY18f earnings

There was no change in status of stranded projects that amount to 10GW, constituting INR240bn (21%) of BHEL's order backlog and INR33bn (9%) of its receivables. Our forecasts are maintained. We do not expect any significant earnings pick-up in FY18f after factoring in wage revision impact due in Jan17.

Sell with TP of INR193/share; large risks to the sector continue

We rollover our TP to Jun16 and raise it to INR193/share (from INR191) based on 15x P/E. Recent surge in orders have eased order inflow concerns while margins concerns have increased on reports of aggressive price bidding. We remain sceptical of any further improvement in the order run rate over our forecast considering the slow pace of resolution of problems relating to the distribution losses, fuel availability and private developers' financial health. Increased competition from other players/solar pose further challenges to BHEL's business. We maintain a Sell rating. Higher coal availability, higher margins and execution are the key risk factors.

Devang Patel, +91 22 66842861 devang.patel@ilfsindia.com

Exhibit 1: Qtrly growth trend in backlog and revenue (%)





Exhibit 2: Qtrly trend in margins



Source: Company, IL&FS Institutional Equities

Source: Company, IL&FS Institutional Equities

Exhibit 3: Order booking trend (INRbn)





Exhibit 4: Order backlog trend (INRbn)



Source: Company, IL&FS Institutional Equities

Source: Company, IL&FS Institutional Equities

Exhibit 5: 1-yr fwd P/E on consensus estimates (x)





Exhibit 6: Consensus EPS revision trend



Source: Bloomberg, IL&FS Institutional Equities

Source: Bloomberg, IL&FS Institutional Equities



Exhibit 7: Quarterly results snapshot

| (INRmn) | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | y-o-y (%) | q-o-q (%) |
|--------------------------|--------|--------|--------|---------|---------|-----------|-----------|
| Net Revenue | 51,550 | 61,440 | 61,980 | 126,860 | 43,617 | -15 | -66 |
| Ү-о-у | -20% | -32% | -28% | -16% | -15% | | |
| Total operating expenses | 49,371 | 58,525 | 59,042 | 110,042 | 45,710 | -7 | -58 |
| Inc/Dec in stock | -6,038 | -3,193 | -3,739 | 9,589 | -4,514 | -25 | -147 |
| RM costs | 32,004 | 37,531 | 37,031 | 66,017 | 28,266 | -12 | -57 |
| Staff costs | 15,771 | 15,956 | 13,622 | 9,152 | 14,615 | -7 | 60 |
| Other expenses | 7,634 | 8,231 | 12,128 | 25,285 | 7,343 | -4 | -71 |
| EBITDA | 2,179 | 2,915 | 2,938 | 16,818 | -2,093 | -196 | -112 |
| Y-o-y | -44% | -52% | -70% | -38% | -196% | | |
| Other income | 3,478 | 1,961 | 2,741 | 160 | 4,924 | 42 | 2,974 |
| Depreciation | 2,725 | 2,662 | 2,565 | 2,821 | 2,425 | -11 | -14 |
| EBIT | 2,932 | 2,214 | 3,114 | 14,157 | 406 | -86 | -97 |
| Interest | 473 | 126 | 52 | 265 | 33 | -93 | -88 |
| Recurring PBT | 2,459 | 2,088 | 3,062 | 13,892 | 373 | -85 | -97 |
| Net extra ordinary items | - | - | - | (101) | - | | |
| PBT (reported) | 2,459 | 2,088 | 3,062 | 13,790 | 373 | -85 | -97 |
| Tax | 524 | 840 | 936 | 4,907 | 34 | -93 | -99 |
| PAT (reported) | 1,935 | 1,248 | 2,126 | 8,884 | 339 | -82 | -96 |
| Adj. Net Income | 1,935 | 1,248 | 2,126 | 9,512 | 339 | -82 | -96 |
| Y-o-y | -58% | -79% | -69% | -48% | -82% | | |
| Adj. EPS (INR) | 0.8 | 0.5 | 0.9 | 3.9 | 0.1 | -82 | -96 |
| Ratios (%) | | | | | | | |
| Gross margin | 49.6 | 44.1 | 46.3 | 40.4 | 45.5 | | |
| EBITDA margin | 4.2 | 4.7 | 4.7 | 13.3 | (4.8) | | |
| EBIT margin | 5.7 | 3.6 | 5.0 | 11.2 | 0.9 | | |
| Other income/PBT | 141.4 | 93.9 | 89.5 | 1.2 | 1,320.1 | | |
| Effective Tax rate | 21.3 | 40.2 | 30.6 | 35.6 | 9.1 | | |
| PAT margin | 3.8 | 2.0 | 3.4 | 7.5 | 0.8 | | |

Source: Company, IL&FS Institutional Equities

Financials and valuations (standalone)

| Income statement (II | NRmn) |
|----------------------|-------|
|----------------------|-------|

| Fiscal year ending | 03/15p | 03/16f | 03/17f | 03/18f |
|------------------------------|---------|---------|---------|---------|
| Total operating income | 301,830 | 295,385 | 363,645 | 442,176 |
| Total operating expenses | 276,979 | 268,697 | 318,883 | 396,872 |
| EBITDA | 24,851 | 26,688 | 44,762 | 45,304 |
| Other income | 8,340 | 11,128 | 14,038 | 15,489 |
| Depreciation | 10,773 | 11,215 | 12,062 | 13,091 |
| EBIT | 22,418 | 26,601 | 46,739 | 47,701 |
| Interest | 917 | 273 | 273 | 273 |
| Recurring PBT | 21,501 | 26,329 | 46,466 | 47,428 |
| Net extra ordinary items | -101 | - | - | - |
| PBT (reported) | 21,400 | 26,329 | 46,466 | 47,428 |
| Total taxes | 6,649 | 8,688 | 15,334 | 15,651 |
| PAT (reported) | 14,751 | 17,640 | 31,132 | 31,777 |
| (+) Share in assoc. earnings | - | - | - | - |
| Less: Minority interest | - | - | - | - |
| Prior period items | -558 | - | - | - |
| Net income (reported) | 14,193 | 17,640 | 31,132 | 31,777 |
| Adj. net income | 14,852 | 17,640 | 31,132 | 31,777 |
| Shares outstanding (mn) | 2,448 | 2,448 | 2,448 | 2,448 |
| Adj. dil. shares (mn) | 2,448 | 2,448 | 2,448 | 2,448 |
| Adj. EPS (INR) | 6.1 | 7.2 | 12.7 | 13.0 |
| Growth ratios (%) | | | | |
| Total operating income | -22.8 | -2.1 | 23.1 | 21.6 |
| EBITDA | -45.0 | 7.4 | 67.7 | 1.2 |
| EBIT | -56.5 | 18.7 | 75.7 | 2.1 |
| Recurring PBT | -57.2 | 22.5 | 76.5 | 2.1 |
| Adj. net income | -56.8 | 18.8 | 76.5 | 2.1 |
| Adj. EPS | -56.8 | 18.8 | 76.5 | 2.1 |
| Operating ratios (%) | | | | |
| EBITDA margin | 8.2 | 9.0 | 12.3 | 10.2 |
| EBIT margin | 7.4 | 9.0 | 12.9 | 10.8 |
| Net profit margin | 4.8 | 5.8 | 8.2 | 6.9 |
| Other income/PBT | 38.8 | 42.3 | 30.2 | 32.7 |
| Effective Tax rate | 31.1 | 33.0 | 33.0 | 33.0 |

Balance sheet (INRmn)

| 03/15p | 03/16f | 03/17f | 03/18f |
|---------|---|-------------|---|
| 4,895 | 4,895 | 4,895 | 4,895 |
| - | - | - | - |
| 335,951 | 350,727 | 373,268 | 396,454 |
| 340,846 | 355,622 | 378,164 | 401,350 |
| - | - | - | - |
| 610 | 610 | 610 | 610 |
| -22,207 | -22,734 | -23,663 | -24,612 |
| 319,249 | 333,499 | 355,110 | 377,348 |
| 125,932 | 130,611 | 145,310 | 154,163 |
| 84,349 | 95,563 | 107,625 | 120,717 |
| 41,583 | 35,047 | 37,685 | 33,446 |
| 5,000 | 9,000 | 5,000 | 7,000 |
| - | - | - | - |
| 4,177 | 4,177 | 4,177 | 4,177 |
| 98,127 | 123,343 | 133,571 | 135,869 |
| 101,017 | 105,206 | 119,554 | 121,144 |
| 376,373 | 371,840 | 404,519 | 446,699 |
| 36,187 | 38,130 | 46,731 | 56,823 |
| 232,811 | 235,221 | 264,693 | 284,804 |
| 110,404 | 118,022 | 131,434 | 143,006 |
| 268,489 | 285,275 | 308,249 | 332,725 |
| 319,249 | 333,499 | 355,110 | 377,348 |
| | 4,895 - 335,951 340,846 - 610 -22,207 319,249 125,932 84,349 41,583 5,000 - 4,177 98,127 101,017 376,373 36,187 232,811 110,404 268,489 | 4,895 4,895 | 4,895 4,895 4,895 335,951 350,727 373,268 340,846 355,622 378,164 |

Cash flow statement (INRmn)

| Fiscal year ending | 03/15p | 03/16f | 03/17f | 03/18f |
|------------------------------|---------|--------|---------|---------|
| Net profit | 14,193 | 17,640 | 31,132 | 31,777 |
| Depreciation | 10,773 | 11,215 | 12,062 | 13,091 |
| Deferred tax | -2,518 | -527 | -929 | -949 |
| Working capital changes | -9,315 | 8,430 | -12,746 | -22,178 |
| Less: Other income | 8,340 | 11,128 | 14,038 | 15,489 |
| Cash flow from operations | 4,794 | 25,630 | 15,481 | 6,253 |
| Capital expenditure | -4,006 | -8,679 | -10,699 | -10,853 |
| Strategic investments | 25 | - | - | - |
| Marketable investments | - | - | - | - |
| Change in other loans & adv. | - | - | - | - |
| Goodwill paid | - | - | - | - |
| Other income | 8,340 | 11,128 | 14,038 | 15,489 |
| Cash flow from investing | 4,359 | 2,449 | 3,339 | 4,636 |
| Equity raised | - | - | - | - |
| Change in borrowings | -25,938 | 0 | 0 | 0 |
| Dividends paid (incl. tax) | -3,322 | -2,864 | -8,591 | -8,591 |
| Others | -496 | 0 | 0 | 0 |
| Cash flow from financing | -29,755 | -2,864 | -8,591 | -8,591 |
| Net change in cash | -20,602 | 25,216 | 10,229 | 2,298 |

Key Ratios

| Fiscal year ending | 03/15p | 03/16f | 03/17f | 03/18f |
|------------------------------|--------|--------|--------|--------|
| Valuation ratios (x) | | | | |
| P/E (on Adj. EPS) | 43.9 | 36.9 | 20.9 | 20.5 |
| P/E (on basic, reported EPS) | 43.9 | 36.9 | 20.9 | 20.5 |
| P/CEPS | 25.4 | 22.6 | 15.1 | 14.5 |
| P/BV | 1.9 | 1.8 | 1.7 | 1.6 |
| Dividend yield (%) | 0.4 | 0.4 | 1.1 | 1.1 |
| Market cap. / Sales | 2.2 | 2.2 | 1.8 | 1.5 |
| EV/Sales | 1.8 | 1.7 | 1.4 | 1.1 |
| EV/EBITDA | 21.4 | 19.0 | 11.1 | 10.9 |
| Net Cash / Market cap. | 15.1 | 18.9 | 20.5 | 20.9 |
| Per share ratios (INR) | | | | |
| Adj. EPS | 6.1 | 7.2 | 12.7 | 13.0 |
| EPS (Basic, reported) | 5.8 | 7.2 | 12.7 | 13.0 |
| Cash EPS | 10.5 | 11.8 | 17.6 | 18.3 |
| Book Value | 139.3 | 145.3 | 154.5 | 164.0 |
| Dividend per share | 1.2 | 1.0 | 3.0 | 3.0 |
| Total assets / equity (x) | 1.0 | 0.9 | 0.9 | 0.9 |
| Return ratios (%) | | | | |
| ROCE | 4.7 | 5.5 | 9.1 | 8.7 |
| ROIC | 7.2 | 8.5 | 15.0 | 14.2 |
| ROE | 4.4 | 5.1 | 8.5 | 8.2 |
| ROA | 4.5 | 5.4 | 9.0 | 8.7 |
| OCF/Sales | 1.8 | 8.7 | 4.3 | 1.4 |
| FCF/Sales | 0.5 | 5.7 | 1.3 | -1.0 |
| Turnover ratios (x) | | | | |
| Asset turnover (x) | 0.9 | 0.9 | 1.1 | 1.2 |
| Gross asset turnover | 2.4 | 2.3 | 2.5 | 2.9 |
| Inventory / Sales (days) | 120.3 | 127.4 | 112.8 | 99.3 |
| Receivables (days) | 469.1 | 462.3 | 389.6 | 351.3 |
| Payables (days) | 539.8 | 525.2 | 451.6 | 404.6 |
| Working capital cycle (days) | 200.4 | 205.3 | 168.9 | 153.3 |
| Solvency ratios (x) | | | | |
| Gross debt to equity | -0.1 | -0.1 | -0.1 | -0.1 |
| Net debt to equity | -0.4 | -0.4 | -0.4 | -0.4 |
| Net debt to EBITDA | -4.8 | -5.5 | -3.5 | -3.5 |
| Interest Coverage (on EBIT) | 24.4 | 97.5 | 171.3 | 174.8 |
| | | | | |



Analyst Certification

The following analyst(s) is(are) primarily responsible for this report and, certifies(y) that the opinion(s) on the subject company(ies) and its security(ies) and any other views or forecasts expressed herein accurately reflect their personal view(s): Devang Patel

Disclosures

Meaning of IL&FS Broking Services Private Limited's equity research ratings

The rating represents the expected change in the price of the stock over a horizon of 12 months.

Buy: more than +15% **Add**: +5% to +15% **Reduce**: -5% to +5% **Sell**: less than -5%

Analyst disclosures

None of the analysts involved in the preparation of this research report or a member of his/her household is an officer, director or supervisory board member of any of the company(ies) that is/are the subject of this research report. None of the analysts involved in the preparation of this research report or members of his/her household hold any financial interest in the securities of the company(ies) that is/are the subject of this research report.

Disclaimer

This document has been prepared by IL&FS Broking Services Private Limited (IBSPL) formerly known as Avendus Securities Private Limited. This document is meant for the use of the intended recipient only. Though dissemination to all intended recipients is simultaneous, not all intended recipients may receive this document at the same time. This document is neither an offer nor solicitation for an offer to buy and/or sell any securities mentioned herein and/or official confirmation of any transaction. This document is provided for assistance only and is not intended to be, and must not be taken as, the sole basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigation as he deems necessary to arrive at an independent evaluation, including the merits and risks involved, for investment in the securities referred to in this document and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors. This document has been prepared on the basis of information obtained from publicly available, accessible resources. IBSPL has not independently verified all the information given in this document. Accordingly, no representation or warranty, express or implied, is made as to accuracy, completeness or fairness of the information and opinion contained in this document. The information given in this document is as of the date of this document and there can be no assurance that future results or events will be consistent with this information. Though IBSPL endeavors to update the information contained herein on reasonable basis, IBSPL, its associate companies, their directors, employees, agents or representatives (IBSPL and its affiliates) are under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent us from doing so. IBSPL and its affiliates expressly disclaim any and all liabilities that may arise from information, error or omission in this connection. IBSPL and its affiliates shall not be liable for any damages whether direct, indirect, special or consequential, including lost revenue or lost profits, which may arise from or in connection with the use of this document. This document is strictly confidential and is being furnished to you solely for your information. This document and/or any portion thereof may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of IBSPL. This document is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of the United States or Canada or is located in any other locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law or regulation or which would subject IBSPL and its affiliates to any registration or licensing requirements within such jurisdiction. Persons in whose possession this document comes should inform themselves about and observe any such restrictions. IBSPL and its affiliates may be performing or seeking to perform investment banking and other services for any company referred to in this document. Affiliates of IBSPL may have issued other reports that are inconsistent with and reach a different conclusion from the information presented in this document.

IBSPL and its affiliates may have interest/positions, financial or otherwise, in the companies mentioned in this document. In order to provide complete transparency to our clients, we have incorporated disclosures about interests of analysts and about potential conflicts of interest of IBSPL and its associate companies in this document. This should, however, not be treated as an endorsement of the view expressed in the document. IBSPL is committed to providing high-quality, objective and unbiased research to our investors. To this end, we have policies in place to identify, consider and manage potential conflicts of interest and protect the integrity of our relationships with investing and corporate clients. Employee compliance with these policies is mandatory. Any comment or statement made herein are solely those of the analyst and do not necessarily reflect those of IBSPL.

OFFICE ADDRESS

IL&FS Broking Services Private Limited

The IL&FS Financial Centre, 3rd Floor, Plot C - 22, G - Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India.

T: +91 22 2653 3333 F: +91 22 2653 3548

IL&FS Broking Services Private Limited - Corporate Identity Number: U67120MH2009PTC191131; SEBI Registration Numbers: BSE CM - INZ010005833 | NSE CM - INZ230005738 | NSE F&O - INZ230005738